Efficacy
| . | n/N (%) . |
|---|---|
| Early response to therapy MRD < 10–4 bone marrow blasts | |
| Poor peripheral blood day 8 blast clearance | 2/34 (5.9%) |
| Day 8 peripheral blood MRD <10−2 | 14/28 (50%) |
| Response to induction | |
| CR | 29/34 (85.3%) (3 induction failures, 1 induction death, and 1 lost to follow-up) |
| Induction failure | 3 (8.8%) |
| After induction phase 1a (week 4) | 22/31 (70.9%) (could not be evaluated in 3 patients [1 death, 1 lost to follow-up, and 1 uninterpretable]) |
| After induction phase 1a plus 1b (week 8) | 27/32 (84.3%) |
| After induction plus consolidation (week 16) | 28/32 (87.5%) |
| . | n/N (%) . |
|---|---|
| Early response to therapy MRD < 10–4 bone marrow blasts | |
| Poor peripheral blood day 8 blast clearance | 2/34 (5.9%) |
| Day 8 peripheral blood MRD <10−2 | 14/28 (50%) |
| Response to induction | |
| CR | 29/34 (85.3%) (3 induction failures, 1 induction death, and 1 lost to follow-up) |
| Induction failure | 3 (8.8%) |
| After induction phase 1a (week 4) | 22/31 (70.9%) (could not be evaluated in 3 patients [1 death, 1 lost to follow-up, and 1 uninterpretable]) |
| After induction phase 1a plus 1b (week 8) | 27/32 (84.3%) |
| After induction plus consolidation (week 16) | 28/32 (87.5%) |